Uso de Sildenafilo oral vs Óxido Nítrico inhalatorio en hipertensión pulmonar persistente en el recién nacido de cuidados intensivos neonatales del Hospital Roberto Gilbert Elizalde de enero del 2018 a julio del 2022.

Abstract

Persistent pulmonary hypertension in the newborn is a relatively frequent pathology today, which up to now has a survival of no more than 7 years, but this is very complex due to the different treatments used for this pathology, in addition to the use of nitric oxide is much lower than that of oral sildenafil, this entails a complication when comparing the therapeutic effects. Conclusions: The comparison between inhaled nitric oxide and sildenafil is the purpose of this thesis work, through the optimal sample of patients with pulmonary hypertension (148 patients) admitted to the NICU area of the "Roberto Gilbert Elizalde" Children's Hospital during the period from January 2018 to July 2022. It was evidenced that there is a higher prevalence in term newborns of the male gender of 66%, 45% of these patients were diagnosed with an age less than 10 days old, patients with optimal Apgar at the first minute were determined in 64%, after five minutes it rose to 75%, The weight of the patients at the time of admission was obtained that only 22% of the patients had a weight less than 1999 grams, 23% of these patients presented a smaller size at 40 cm at the time of admission. Regarding the diseases associated with patients with persistent pulmonary hypertension in the newborn, it was shown that there is a prevalence of 30%, among the most mentioned are respiratory distress, pulmonary dysplasias, neonatal sepsis and cardiovascular malformations, 65%. of these patients were treated with sildenafil orally compared to 35% treated with nitric oxide, a direct correlation was found between mortality and low height, weight and Apgar score. The therapeutic effects in comparison of Sildenafil vs. nitric oxide showed greater survival effectiveness in patients with treatment with nitric oxide.